1. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
- Author
-
Chen, Guanglong, Gong, Ting, Wang, Zhe, Wang, Zeyu, Lin, Xiaolin, Chen, Sunrui, Sun, Chu, Zhao, Weijie, Kong, Ye, Ai, Huihan, Yang, Hang, Liu, Yusheng, Wu, Fangyan, Kang, Jiawei, Zhao, Shasha, Xiao, Xiuying, Sun, Jing, He, Aina, and Li, Zhi
- Subjects
COLORECTAL cancer ,RNA sequencing ,DRUG resistance ,OXIDATIVE phosphorylation ,CELL populations - Abstract
Purpose: Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal cancer (CRC) patients. However, chemoresistance-induced resistance is an essential cause for mortality. Therefore, it is necessary to study the mechanism of drug resistance in CRC. Methods: Here, we established two strains of patient-derived organoids (PDOs) selected from oxaliplatin-resistant and treatment-naïve CRC patients. To dissect the drug-resistant mechanisms, these CRC-PDOs were subjected to single-cell RNA sequencing (scRNA-Seq). Results: We found that the drug sensitivity test outcome from these organoids subjected to oxaliplatin and 5-FU exposure was consistent with the clinic readout. CRC-PDOs well recapitulated the morphology and histology of their parental biopsies based on HE and IHC staining of pathological biomarkers. The scRNA-Seq data filtered drug-resistant cell populations and related signaling pathways (e.g. oxidative phosphorylation and ATP metabolic process). The data also revealed several putative drug resistant-driven genes (STMN1, VEGFA and NDRG1) and transcription factors (E2F1, BRCA1, MYBL2, CDX2 and CDX1). Conclusion: We generated an oxaliplatin-resistant CRC organoid model that was employed to provide potential therapeutic targets for treating CRC patients exhibiting oxaliplatin-resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF